疏肝理脾片抗大鼠免疫性肝纤维化研究  

Study of Shuganlipi Tablet on Anti-hepatic Fibrosis of Rats

作　　者：褚裕义[1] 孙克伟[1] 刘伟士[1] 谌宁生[1] 王伟华[1] 刘明德[1] 

机构地区：[1]湖南中医学院第一附属医院肝病中心,长沙410007

出　　处：《中国中西医结合脾胃杂志》1998年第2期98-100,共3页

基　　金：国家"八五"科技攻关项目

摘　　要：为研究疏肝理脾片抗肝纤维化的作用，采用牛血清白蛋白（BSA）致大鼠免疫损伤性肝纤维化模型，观察肝纤维组织增生程度、肝羟脯氨酸（Hyp）含量和血清透明质酸（HA）、肝功能变化。结果：疏肝理脾片能明显降低鼠肝Hyp含量，减轻肝纤维组织增生程度，并明显提高血清白蛋白水平。提示疏肝理脾片具有明显的抗BSA致大鼠肝纤维化的作用。To observe the effect of anti-hepatic fibrosis of Shuganlipi Tablet. Method:Immuno-injured hepatic fibrosis of rats was induced by bovine serum albumin. The contents ofcollagen. Patho-fogy of liuer and serum hyaluronic acid (HA) transaminase and albumin wasstudied. Results: The contents of collagen and degree of hepatic fibrosis in Shuganlipi Tabletgroups was remarkably decreased compared with the model group (P <0. 05). And its serumalbumin significantly incerased. Conclusion: Shuganlipi tablet has a positive effect on anti-hepaticfibrosis of rats induced by bovine serum albumin.

关 键 词：肝纤维化 大鼠 疏肝理脾片 

分 类 号：R575.2[医药卫生—消化系统]